Health & Biotech
Incannex Healthcare Limited (IHL.ASX) is a clinical stage pharmaceutical development company developing unique medicinal cannabis pharmaceutical products and psychedelic medicine therapies for the treatment of Generalised Anxiety Disorder (GAD), Obstructive Sleep Apnoea (OSA), Traumatic Brain Injury (TBI)/Concussion, rheumatoid arthritis, inflammatory bowel disease and inflammatory lung conditions (ARDS, COPD, Asthma, Bronchitis).
FDA registration and marketing approval, subject to ongoing clinical success, is being pursued for each product and therapy under development.
Each indication represents major global markets and currently have either no, or limited, existing registered pharmacotherapy (drug) treatments available to the public, raising the possibility of patients receiving Government subsidies for products that demonstrate suitable safety and efficacy profiles in clinical trials.
Incannex has a strong patent filing strategy as it develops its products and therapies in conjunction with its medical and scientific advisory board and its collaborative partners, including Monash University and The Alfred Hospital.
KEY PEOPLE
RELATED STOCKHEAD STORIES
News
Quarterly wrap: Incannex and Neurotech focus on advancing clinical trials
Health & Biotech
Share and option holders in early counting overwhelmingly supporting Incannex’s move to redomicile to US with sole NASDAQ listing
News
In Case You Missed It: O&G production, a graphite plant and a Chilean gold anomaly
Health & Biotech
Clinical results for ancient therapy help ASX cannabis stocks weed out competition
News
In Case You Missed It: Construction materials player beats resources for top spot
Health & Biotech
Weed Week: ‘Welcome to the psychedelic 2020s!’ as market holds breath on key US approval
Health & Biotech
‘Frontrunner within the psychedelics’ : Incannex prepares to file psilocybin US FDA application ahead of Nasdaq Uplisting
Health & Biotech
Incannex gets green light from US FDA for Phase 2/3 Pivotal Clinical Trialfor obstructive sleep apnoea
Health & Biotech
Incannex’s subsidiary Clarion Clinics prepares to take first clients for psychedelic treatment
Health & Biotech
Incannex has positive Pre-IND meeting with US FDA on IHL-675A for treatment of Rheumatoid Arthritis
News
ASX Health Stocks: Living Cells Tech files a patent for cannabis-based dementia drug
Health & Biotech
Incannex submits key application to US FA for IHL-42X for treatment of obstructive sleep apnoea
Health & Biotech
MDMA and magic mushrooms have arrived: Australia lets psychs find a new way for happy to fight sad
Tech
These tech and pharma stocks are looking to M&A to drive growth in global markets
Health & Biotech
ASX Health Stocks: Successful toxicology tests pave the way for PYC’s Phase 2 clinical trial
Health & Biotech
Incannex engages Fortrea for major clinical trial looking at IHL-42X for sleep apnoea
News